May 2025 in “The Journal of Rheumatology” Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.
148 citations
,
March 2022 in “The New England Journal of Medicine” Baricitinib was effective in treating alopecia areata in two major trials.
34 citations
,
August 2002 in “British Journal of Dermatology” ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.
October 2023 in “Frontiers in Medicine” Dupilumab helped a 4-year-old grow hair back after another treatment failed.
19 citations
,
May 1992 in “International Journal of Dermatology” Some alternative vitiligo treatments show promise, but none are as effective as psoralens and UVA.
18 citations
,
February 2025 in “Drug Delivery and Translational Research” The microneedle patches effectively treat allergic conjunctivitis with controlled, sustained release of medication.
3 citations
,
July 2019 in “Supportive Care in Cancer” The lotion CG428 did not show effectiveness in treating permanent hair loss in breast cancer survivors.
September 2023 in “Journal of the American Academy of Dermatology” 16 citations
,
May 2006 in “The Journal of Dermatology” Peeling skin syndrome was successfully treated with a vitamin D cream.
9 citations
,
February 2002 in “International Journal of Dermatology” The patient's symptoms improved with treatment but recurred when the steroid dose was reduced, requiring ongoing therapy.
2 citations
,
November 2007 in “Clinics in dermatology” Tofacitinib may be an effective and safe treatment for adolescent alopecia areata.
15 citations
,
October 2022 in “Allergy” Dupilumab treatment reduces Th2-related markers and helps hair growth in alopecia areata, showing Th2's role in the condition.
30 citations
,
May 2016 in “Expert Opinion on Biological Therapy” New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.
5 citations
,
March 2012 in “Veterinary dermatology” A cat developed a skin lesion from a topical solution, which healed with minoxidil treatment.
June 2024 in “Frontiers in immunology” Sequential therapy with dupilumab and baricitinib improved hair regrowth and atopic dermatitis in a child without adverse reactions.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” Topical gabapentin was safe and effective for treating scalp symptoms and promoting hair regrowth in cicatricial alopecias.
April 2021 in “Research Square (Research Square)” The new cocrystal KET-PABA is a more effective and safe anti-inflammatory treatment for skin conditions in mice.
August 2016 in “Journal of Investigative Dermatology” Blocking the CCR5 receptor may be a new way to treat hair loss from alopecia areata.
May 2025 in “The Journal of Rheumatology” Anti-CD19 therapy may help treat SLE and NMOSD.
1 citations
,
September 2023 in “JAAD case reports” Mogamulizumab, a skin cancer drug, may cause hair loss similar to alopecia areata.
February 2026 in “Medicina” Hyaluronic Acid Profhilo® reduces skin inflammation and nerve-related pain in atopic dermatitis.
Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.
1 citations
,
November 2018 in “Therapeutic Delivery” New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
16 citations
,
March 2015 in “Clinical and experimental dermatology” Mycophenolic acid may help treat hair loss by promoting hair growth and cell proliferation.
8 citations
,
January 2020 in “Indian Dermatology Online Journal” PRP works faster and is a safe alternative to steroids for treating alopecia areata.
June 2023 in “Small animal advances” Selamectin spot-on effectively treats scabies in rabbits.
July 2023 in “Clinical and Experimental Dermatology” Combining baricitinib with low-dose corticosteroids significantly improved severe hair loss in eight patients.
January 2022 in “Drugs of Today” Minoxidil and a solvent mixture can prevent hair loss caused by chemotherapy in mice.
July 2025 in “Journal of Investigative Dermatology” Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.